Biogen Inc. (ETR:IDP)
133.00
-1.45 (-1.08%)
Nov 7, 2025, 5:35 PM CET
Biogen Revenue
Biogen had revenue of $2.53B USD in the quarter ending September 30, 2025, with 2.79% growth. This brings the company's revenue in the last twelve months to $10.07B, up 4.77% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.07B
Revenue Growth
+4.77%
P/S Ratio
2.30
Revenue / Employee
$1.32M
Employees
7,605
Market Cap
19.70B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Biogen News
- 3 days ago - Stifel Upgrades Biogen (BIIB) to 'Buy', Raises Price Target to $202 | BIIB Stock News - GuruFocus
- 3 days ago - Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - 24/7 Wall street
- 3 days ago - Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment - CNBC
- 6 days ago - BIIB: Bernstein Raises Price Target for Biogen to $157 with Market Perform Rating | BIIB Stock News - GuruFocus
- 6 days ago - Biogen (BIIB) Reveals New Data on Felzartamab at Kidney Week 2025 - GuruFocus
- 6 days ago - Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 - GlobeNewsWire
- 9 days ago - Biogen (BIIB) Rating Maintained as RBC Capital Lowers Price Target | BIIB Stock News - GuruFocus
- 10 days ago - Decoding Biogen Inc (BIIB): A Strategic SWOT Insight - GuruFocus